Advanced Therapeutics Program (ATRx)

We started with cardiometabolic diseases because of the devastating impact these diseases have on our patient's health, and the opportunity to help our PCPs slow the progression of their conditions. Through these collaborative efforts, we can prevent long-term suffering and improve the health and well-being of the people in the communities we serve.

Michael Hyder, MD, MPH, FACC | Clinical Chief, Pharmacotherapies, Department of Medicine

Donate to UMass Memorial Health

Learn more about giving to UMass Memorial Health